Neumora (NMRA) Chief Operating & Development Officer Aurora Singh Exercises Options and Sells Shares

What Happened

• Aurora Daljit Singh, Chief Operating and Development Officer of Neumora Therapeutics (NMRA), exercised multiple stock option tranches (reported as code M) at $0.72 per share and concurrently sold shares in the open market (code S). The filing shows approximately 243,753 shares acquired by exercise (cash paid ≈ $175,504) and approximately 277,773 shares sold for aggregate cash proceeds of ≈ $431,675. The net proceeds before taxes/fees were roughly $256,171.
• The filing also shows the corresponding derivative interests (options) being reported as disposed at $0.00 per share as part of the exercise reporting (standard Form 4 presentation).

Key Details

• Transaction dates: primarily 2026-08-17 through 2026-08-19.
• Exercise price: $0.72 per share; aggregate cash paid for exercises ≈ $175,504.
• Open‑market sale prices: sales executed across a range (~$1.46 to $1.7006 per share depending on trade); weighted‑average sale proceeds reported totaling ≈ $431,675.
• Shares sold (sum of reported open‑market sales): ~277,773; shares acquired by exercise: ~243,753.
• Shares owned after transaction: not specified in the provided filing details.
• Notable footnotes: several sales were executed in multiple trades at price ranges (filing includes footnotes F1, F2, F4, F9–F12 describing price ranges and weighted averages). F3 notes some shares are held by the Aurora Family Trust. Vesting/option details for various grants are included in F5–F8.
• Timeliness: Report filed 2026-08-19 for transactions through 2026-08-17 — appears timely under Form 4 reporting requirements (no late filing indicated).

Context

• This was an options exercise followed by open‑market sales (commonly a cash exercise and immediate sale rather than a stock retention), as shown by the paired exercise (M) and sale (S) entries and the $0.00 derivative disposition lines (which reflect the extinguished options).
• Such transactions are often routine (exercising vested options and monetizing shares) and do not, by themselves, indicate management’s forward view of the company. The filing is factual; motivations and tax/fee impacts are not disclosed.